ALNY News and Press, Alnylam Pharmaceuticals Inc. From 09/26/21

Read the full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The political showdown over the government debt ceiling is likely to ramp up next week. While U.S. government shutdowns ...

− If Approved, Vutrisiran will Provide a New, Subcutaneously Administered, Once-Quarterly Treatment Option for Patients with hATTR Amyloidosis − Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submiss...

- Subgroup Analyses and Exploratory Endpoints Demonstrated that Vutrisiran Improved Important Areas of Patient Health and Function Compared with Placebo at 9 Months – - Additional Analyses Showed Similar Improvements in Progression of Neuropathy and Quality of Life Meas...

Shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) traded at a new 52-week high today of $209.47. So far today approximately 118,000 shares have been exchanged, as compared to an average 30-day volume of 641,000 shares. In the past 52 weeks, Alnylam Pharmaceuticals Inc. share prices ar...

Alnylam reported second quarter results that included modest outperformance in product revenue, including 12% qoq growth in Onpattro. 2022 should be a big year for the ATTR-CM program, with APOLLO-B results and a possible early look at HELIOS-B. Intellia's NTLA-2001 showed encoura...

Shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) traded at a new 52-week high today of $203.31. So far today approximately 118,000 shares have been exchanged, as compared to an average 30-day volume of 678,000 shares. Over the past year, Alnylam Pharmaceuticals Inc. has traded in a r...

− Full Study Enrollment Completed Well Ahead of Schedule − Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its HELIOS-B Phase 3 study of vutrisiran, an ...

Image source: The Motley Fool. Alnylam Pharmaceuticals, inc (NASDAQ: ALNY) Q2 2021 Earnings Call Aug 3, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Alnylam Pharmaceuticals, inc (ALNY) Q2 2021 Earnings Call Trans...

Alnylam Pharmaceuticals, Inc. Q2 2021 Earnings Conference Call Aug 3, 2021 8:30 AM ET Company Participants Christine Lindenboom - Investor Relations John Maraganore - Chief Executive Officer Tolga Tanguler - Chief Commercial Officer Akshay Vaishnaw - President of Research and Development Jeff...